Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Current assets:
Cash, cash equivalents and restricted cash	$ 102,685,000	$ 110,891,000
Available-for-sale securities, at fair value	578,276,000	292,735,000
Prepaid expenses	9,537,000	8,813,000
Other current assets	4,973,000	4,033,000
Total current assets	695,471,000	416,472,000
Property, plant and equipment, net	386,032,000	290,262,000
Intangible assets, net	8,562,000	10,262,000
Right-of-use assets	45,255,000	45,297,000
Other assets	4,482,000	3,259,000
Total Assets	1,139,802,000	765,552,000
Current liabilities:
Accounts payable	11,388,000	35,866,000
Accrued expenses	63,017,000	39,763,000
Accrued payroll and benefits	21,989,000	17,963,000
Lease liabilities	6,342,000	10,563,000
Deferred revenue	0	866,000
Other liabilities	432,000	435,000
Total current liabilities	103,168,000	105,456,000
Long-term liabilities:
Lease liabilities, net of current portion	111,027,000	104,608,000
Liability related to the sale of future royalties	341,361,000	268,326,000
Credit facility	393,183,000	0
Total long-term liabilities	845,571,000	372,934,000
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders' equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,376 and 107,312 shares	217,000	200,000
Additional paid-in capital	1,806,000,000	1,300,395,000
Accumulated other comprehensive income (loss)	4,750,000	(3,222,000)
Accumulated deficit	(1,625,523,000)	(1,026,030,000)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	185,444,000	271,343,000
Noncontrolling interest	5,619,000	15,819,000
Total noncontrolling interest and stockholders' equity	191,063,000	287,162,000
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	$ 1,139,802,000	$ 765,552,000